, not surprisingly, was the volume leader in extra-session Instinet trading as details began to emerge from the company's midquarter update.
The chip giant was ticking down 0.4% to $32.85 after the company
forecast first-quarter revenue of $6.6 billion to $6.9 billion, eliminating both the high and low ends of its previous estimates. In regular Nasdaq trading, Intel tacked on 2 cents to $32.98.
, as usual, was among the volume leaders, but on Thursday the company actually had news. On a conference call with analysts, the company said it still expects revenue in the current quarter to rise sequentially, but Sun executives again indicated that orders could come in too late in the quarter to be counted toward the top line. The stock was up 4.1% to $9.19.
, the biggest Nasdaq loser of the day, slipped another 1.7% to $19.30. The biotech company's stock fell more than 58% in regular action after the Food and Drug Administration said its allergy drug
wasn't yet approvable.
Nasdaq 100 Unit Trust
was up 0.1%, as was
was inching up 0.2%.
was off 0.2%, and
was up 0.1%,
was down 0.3%, and the
S&P 500 Depositary Receipts
were ticking ahead by 0.1%.
, which has been the subject of several Herb Greenberg articles on
, was tanking 23.7% to $8 after the bell. Following the close, the car-shipping company, which is under investigation by the Securities and Exchange Commission, said three directors have resigned from the board of directors.